All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Insmed's DPP-1 inhibitor Brinsupri wins FDA approval for non-cystic fibrosis bronchiectasis treatment
Small molecule, respiratory disease, DPP-1 inhibitor, bronchiectasis, non-cystic fibrosis - Read more

THE GOOD
Business Development & Partnerships

Sever Pharma, Silo Pharma expand partnership to advance ketamine-based implant for chronic pain treatment
Co-development, chronic pain, drug delivery, small molecule, manufacturing, non-opioid - Read more

Eli Lilly, UK Government launch £85M ($114M) innovation program to develop new obesity care models across NHS
Obesity care, public-private partnership, healthcare innovation, UK, funding agreement, research collaboration - Read more

Bayer, Kumquat Biosciences partner on KRAS G12D cancer inhibitor in potential $1.3B deal
Licensing deal, oncology, small molecule, milestone payments, royalties - Read more

Summit Pharmaceuticals partners with Accelerated Biosciences for exclusive distribution of human trophoblast stem cells in Japan
Distributorship agreement, cell therapy, stem cells, regenerative medicine, Japan market - Read more

Rakovina Therapeutics, NanoPalm form joint venture for AI-discovered oncology therapies with lipid nanoparticle delivery
Joint venture, oncology, AI/ML, small molecule, drug discovery, lipid nanoparticle - Read more

Amphastar, Nanjing Anji Biotech partner on three proprietary peptides for US/Canada markets, potential $453M deal value
Licensing deal, oncology, peptide therapeutics, milestone payments, ophthalmology, US-Canada - Read more

Summit Therapeutics skips quarterly call as AstraZeneca ivonescimab deal rumors fly
Licensing deal, oncology, antibody, milestone payments, R&D - Read more

PRESENTED BY YOU?
Get the attention of 2000+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

Novartis' ianalumab hits Ph3 endpoint for primary immune thrombocytopenia, showing extended disease control with BAFF-R targeting
Antibody, autoimmune, monoclonal antibody, primary immune thrombocytopenia, BAFF-R target, B-cell depletion - Read more

Eli Lilly's Jaypirca (pirtobrutinib) outperforms Imbruvica in Ph3 trial for chronic lymphocytic leukemia/small lymphocytic lymphoma
Small molecule, cancer, BTK inhibitor, chronic lymphocytic leukemia, non-covalent inhibitor, treatment-naïve - Read more

Pfizer, Merck & Co.'s Padcev-Keytruda combo shows survival benefit in Ph3 muscle-invasive bladder cancer surgery trial
Antibody-drug conjugate, cancer, monoclonal antibody, bladder cancer, combination therapy, immune checkpoint inhibitor - Read more

THE GOOD
Company Launches

PureTech launches Celea Therapeutics, new biotech focused on respiratory disease drug development
Company launch, rare disease, respiratory disease, small molecule, R&D - Read more

THE GOOD
Fundraises

Tahoe Therapeutics raises $30M funding for AI-powered human cell models for drug design
AI/ML platform, drug discovery, single-cell analysis, platform technology, precision medicine - Read more

SetPoint Medical raises $140M Series C/D for neuroimmune therapy commercialization in autoimmune diseases
Autoimmune, neuroimmune modulation, rheumatoid arthritis, clinical-stage, platform technology - Read more

Gameto raises $44M Series C, advancing stem cell therapies for reproductive health and late-stage Fertilo trial
Reproductive health, stem cell therapy, fertility, clinical-stage, iPSC technology - Read more

Jocasta Neuroscience raises $35M Series A, developing longevity protein for cognitive impairment treatment
Neurological, longevity, preclinical, protein-based, cognitive impairment, neurodegenerative disease - Read more

THE GOOD
Investments

AbbVie plans $195M Illinois API plant as part of $10B US investment amid Trump tariff threats
Small molecule, neurological, manufacturing, investment, strategic - Read more

THE BAD
Approvals & Labels

FDA may deny renewed authorization for Pfizer's pediatric COVID vaccine
mRNA vaccine, infectious disease, regulatory, operational - Read more

THE BAD
Clinical Trials

Biohaven halts troriluzole development in obsessive-compulsive disorder after Ph3 failure
Small molecule, neurological, prodrug, obsessive-compulsive disorder, failed trial, spinocerebellar ataxia - Read more

HHS stops Vaxart's Phase IIb trial of oral COVID-19 vaccine, second freeze since February
Oral vaccine, infectious disease, COVID-19, regulatory, strategic, government funding - Read more

THE UGLY
Lawsuits

Texas sues Eli Lilly over alleged kickback schemes for Mounjaro, Zepbound prescriptions; company vows defense
Diabetes treatment, obesity treatment, legal dispute, regulatory, financial risk - Read more

THE UGLY
Politics & Policy

NIH director cites public distrust, not efficacy, as reason for halting federal mRNA vaccine programs
mRNA vaccine, infectious disease, regulatory, public opinion, funding cuts - Read more

ARPA-H Chief Data Officer resigns after Kennedy cuts $500M in mRNA vaccine research funding
mRNA vaccine, infectious disease, regulatory, strategic, government funding - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here